The main objective of this study is to determine the effects of curcumin on left ventricular function in patients undergoing dialysis. The clinical trial will be conducted double-blind, controlled, single centered. Included patients who have chronic kidney failure undergoing dialysis, and the age range of 30-60 years. Patients who are considered outside the age range or known cardiac disease such as CAD or moderate to severe valvular insufficiency (diagnosed by history and noninvasive tests) and informed refusal of consent have excluded. patients will be divided into two groups:case and control. the case group will receive capsule of curcumin 500 mg per 8 hours for six weeks. the control group will receive placebo with the same dose. Before and after six weeks of intervention echocardiography will do and left ventricular ejection fraction that represents left ventricular function and size of the left ventricle will be measured in both groups.